Study Design: Retrospective analysis of a Medicare database (2005 to 2012).
Objective: To study postoperative complication rates following thoracolumbar fusion for traumatic thoracolumbar fracture in patients with ankylosing spondylitis (AS) compared with patients without AS.
Methods: The PearlDiver database (2005 to 2012) was queried to examine postoperative complication rates in patients with AS undergoing posterior thoracolumbar fusion for thoracolumbar fracture ( = 968). Complication rates were compared with proportion-matched controls without AS undergoing the same procedure ( = 1,979). We examined and compared the incidence of death, postoperative infection, transfusion, venous thromboembolism, respiratory failure, pneumonia, myocardial infarction, urinary tract infection, and acute renal failure in each cohort within 90 days postoperatively.
Results: Patients with AS had significantly higher rates of surgical site infection (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.2 to 2.2, = 0.002), day-of-surgery transfusion rates (OR 1.5, 95% CI 1.3 to 1.8, < 0.0001), respiratory failure (OR 1.8, 95% CI 1.3 to 2.5, = 0.0006), pneumonia (OR 1.8, 95% CI 1.3 to 2.5, = 0.0002), acute renal failure (OR 1.6, 95% CI 1.2 to 2.3, = 0.005), and total medical complications (OR 1.5, 95% CI 1.2 to 1.9, < 0.0001). Ninety-day mortality was not different between the two cohorts ( = 0.18).
Conclusions: Thoracolumbar fusion for thoracolumbar fracture in patients with AS is associated with increased rates of surgical site infection, transfusion, respiratory failure, pneumonia, and acute renal failure postoperatively compared with patients without AS. The level of evidence in this study was III.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5400163 | PMC |
http://dx.doi.org/10.1055/s-0036-1583175 | DOI Listing |
J Neurosurg
January 2025
Departments of1Neurological Surgery.
Objective: Tumor consistency, or fibrosity, affects the ability to optimally resect meningiomas, especially with recent trends evolving toward minimally invasive approaches. The authors' team previously validated a practical 5-point scale for intraoperative grading of meningioma consistency. The impact of meningioma consistency on surgical management and outcomes, however, has yet to be explored.
View Article and Find Full Text PDFJ Neurosurg
January 2025
13Department of Neurosurgery, Shimane Prefectural Central Hospital, Shimane, Japan.
Objective: Aneurysmal subarachnoid hemorrhage (SAH) is associated with high morbidity and mortality rates. In particular, functional outcomes of SAH caused by large or giant (≥ 10 mm) ruptured intracranial aneurysms are worsened by high procedure-related complication rates. However, studies describing the risk factors for poor functional outcomes specific to ruptured large/giant aneurysms are sparse.
View Article and Find Full Text PDFJ Neurosurg Spine
January 2025
15Department of Neurological Surgery, University of California, San Francisco, California.
Objective: The goal of this study was to compare the impact of using a lower thoracic (LT) versus upper lumbar (UL) level as the upper instrumented vertebra (UIV) on clinical and radiographic outcomes following minimally invasive surgery for adult spinal deformity.
Methods: A multicenter retrospective study design was used. Inclusion criteria were age ≥ 18 years, and one of the following: coronal Cobb angle > 20°, sagittal vertical axis > 50 mm, pelvic tilt > 20°, pelvic incidence-lumbar lordosis mismatch > 10°.
Otol Neurotol
February 2025
Department of Otorhinolaryngology-Head and Neck Surgery, Donders Center for Neuroscience, Radboud University Medical Center, Radboud University, Nijmegen, the Netherlands.
Objective: To compare the 3-year outcomes of the modified minimally invasive Ponto surgery (m-MIPS) to both the original MIPS (o-MIPS) and linear incision technique with soft tissue preservation (LIT-TP) for inserting bone-anchored hearing implants (BAHIs).
Study Design: Prospective study with three patient groups: m-MIPS, o-MIPS, and LIT-TP.
Setting: Tertiary referral center.
PLoS One
January 2025
Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, United States of America.
Background: Belatacept is approved for the prophylaxis of organ rejection in Epstein-Barr virus (EBV)-seropositive kidney transplant recipients and is associated with a risk of post-transplant lymphoproliferative disorder (PTLD).
Methods: Data from the Organ Procurement and Transplantation Network were used to examine patterns of belatacept use, describe patient characteristics, and estimate risk of PTLD in EBV-seropositive, kidney-only transplant recipients receiving belatacept- or calcineurin inhibitor (CNI)-based immunosuppression as part of US Food and Drug Administration-mandated safety monitoring.
Results: During the study period (June 15, 2011-June 14, 2016), 94.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!